High-dose bosentan in the prevention and treatment of subarachnoid hemorrhage-induced cerebral vasospasm: An open-label feasibility study

---

Copy For Citation

Nogueira R. G., Bodock M. J., Koroshetz W. J., Topcuoglu M. A., Carter B. S., Ogilvy C. S., ...More

NEUROCRITICAL CARE, vol.7, no.3, pp.194-202, 2007 (SCI-Expanded)

• Publication Type: Article / Article
• Volume: 7 Issue: 3
• Publication Date: 2007
• Doi Number: 10.1007/s12028-007-0070-4
• Journal Name: NEUROCRITICAL CARE
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Page Numbers: pp.194-202
• Hacettepe University Affiliated: Yes

Abstract

Objective To evaluate the safety of high-dosages of the endothelin ETA/B receptor antagonist bosentan in SAH patients at high-vasospasm risk.